Christophe Guignabert
Christophe Guignabert, PhD is an expert in Pulmonology at Bicêtre Hospital (France). As of July 2026, ScienceLeadR ranks Christophe Guignabert in the top 1% of experts worldwide for Hypertension and Hypertension, Pulmonary. Christophe Guignabert has authored 254 publications, the most recent in 2026. SLR score: 1,031 (community average: 125). How the SLR is computed.
LeadR Profile
Pulmonology
Subspecialties: Cardiology - Biochemistry - Critical Care
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Christophe Guignabert, Ph.D, ATSF, FERS
Directeur de Recherche (DR1) / Directeur d'Équipe
Professor of Molecular Biology & Physiology, leading the INSERM team “Endothelial Dysfunction & Therapeutic Innovation in Pulmonary Hypertension” at Université Paris-Saclay, France. My research focuses on the molecular and cellular mechanisms of vascular remodeling in Pulmonary Hypertension, aiming to identify novel therapeutic targets. I am particularly interested in BMP/TGF-β dysregulation, pulmonary endothelial heterogeneity, and endothelial-microenvironment interactions.
Organizations
Career arc: 2001 - 2026
Number : 254
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension. PMID 42381513 — cells, hypertension, lung, hypertension, pulmonary, growth, vascular endothelial growth factor a, macrophages, cardiovascular system, therapeutics | Cardiovasc Res | 2026 | 2 |
| Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension. PMID 42160453 — bone morphogenetic proteins, genes, hypertension, blood, bone morphogenetic protein receptors, type ii, biomarkers, pulmonary arterial hypertension, therapeutics | Sci Transl Med | 2026 | 1 |
| Impact of pulmonary arterial hypertension therapies on gas exchange in portopulmonary hypertension. PMID 42066896 — hypertension, pulmonary arterial hypertension, therapeutics | Chest | 2026 | 0 |
| Bile Acid Alteration and Alveolar Dysfunction in Cirrhosis: An Aggravating Factor or a New Piece in the Pathogenesis of Hepatopulmonary Syndrome? PMID 42050867 — bile, lung, hepatopulmonary syndrome | Am J Respir Cell Mol Biol | 2026 | 0 |
| Novel Role of Von Willebrand Factor-αvβ3 Integrin in Human Pulmonary Artery Smooth Muscle Cell. PMID 42045016 — cells, muscle cells, lung, integrins, muscles, muscle, smooth, pulmonary artery, von willebrand factor, arteries, myocytes, smooth muscle | Am J Respir Cell Mol Biol | 2026 | 0 |
LeadR Networks
Main global connection map